baber/WOPTO huggingface dataset:
Patent SK-284635-B6 (SK)
Title: Thermal regenerator of the photothermic piston engine with impulse steam generation
Inventor: ZUPA JAN
IPC: F01K21/02
Filed: 2003-05-12
Abstract: The thermal regenerator of photothermic piston motor with impulse generation of steam is composed of a capillary porous high-temperature body (1) positioned below an optically permeable cover (3), which entrance of a working substance to the interior space is equipped with a conversion fluid injection jet (5), positioned on side mantle (2) of the photothermic cylinder head and outlet of working substance from the interior space is made on the cylinder mantle (6) positioned and by piston (8) timing the exhaust channel (7). The essence of the solution is that minimum at the end of expansion movement of the piston (8) is the exhaust channel (7) connected with collecting space, which is created between bottom of the piston (8) and to the bottom distantly fixed of the piston fixed a steam-permeable capillary porous low-temperature body (9), is connected with outside through its capillaries, whereby minimum at the end of compression movement of the piston (8) is the evaporation surface (10) which is created, on the outside of the capillary porous low-temperature body (99) occurred in the injection range of a conversion fluid injection jet (5), positioned in the space between of a capillary porous high-temperature body (1) and capillary porous low-temperature body (9).
Patent SK-286585-B6 (SK)
Title: Hydroprocessing catalyst and use thereof
Inventor: ABE SATOSHI
IPC: B01J23/00
Filed: 2001-12-20
Abstract: The invention pertains to a hydroprocessing catalyst suitable for the conversion of heavy hydrocarbon oils, which comprises 7 to 20 weight% of Group VI metal, Calculated as trioxide, and 0.5 to 6 weight % of Group VIII metal, calculated as oxide, on a carrier comprising alumina, the catalyst having a surface area of 100 to  180 m2/g; a total pore volume of 0.55 ml/g or more, a %PV (>200 Ad)  of at least 50%, a %PV(>1000 A d) of at least 5%, a %PV(100 to 1200 A d) of at least 85%, a %PV(>4,000 A d) of 0 to 2%, and a %PV( 10000 >00 A d) of 0 to 1%. The catalyst of the present invention shows improved metals and asphaltene removal, combined with appropriate sulfur, nitrogen, and Conradson carbon removal. Additionally, the catalyst shows a decrease in sediment formation and an improved conversion in ebullating bed operations. In fixed bed operation, the catalyst produces product with an improved storage stability. The invention also pertains to a process for hydroprocessing heavy hydrocarbon feeds with the catalyst according to the invention in fixed bed or ebullating bed operation. >
Patent CZ-298822-B6 (CZ)
Title: Terminal crimping quality decision method/device
Inventor: ISHIBASHI TERUYUKI
IPC: G01R31/00
Filed: 2000-07-21
Abstract: In the present invention, there is disclosed a terminal crimping quality decision method for determining the quality of a terminal crimped on a core of an electrical cable by a terminal crimping device, said method using a characteristic value envelop of characteristic values obtained when the terminal is crimped on the core, said method comprising the steps of: obtaining a reference value envelop of characteristic values obtained when a terminal is correctly crimped on the core, calculating an increment envelop of said reference value envelop to obtain at least one singular point (A, B, C, D) of said reference value envelop, and determining the quality of a terminal crimped by the terminal crimping device based on a characteristic value envelop of said crimped terminal, said characteristic value envelop being obtained in an envelop division separated by said at least one singular point (A, B, C, D). Disclosed is also a terminal crimping quality decision device determining terminal crimping quality.
Patent CZ-300505-B6 (CZ)
Title: Vaccine preparation
Inventor: SOERENSEN BIRGER
IPC: G01N33/569
Filed: 2000-03-02
Abstract: In the present invention, there is disclosed a vaccine preparation comprising peptides SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 11 and SEQ ID NO: 18, where the terminal groups of the sequences may be free carboxyl or amino groups, amide groups, acetyl groups or salts thereof, together with pharmaceutically suitable diluent and eventually with adjuvants, carrier matter and/or vehicle and eventually with other immunostimulating compound or compounds. The invention makes advantage of new and modified peptides, which can induce HIV-1 specific proliferative immune responses without antagonizing the cytotoxic T-cell activity, in order to meet the need for an effective prophylactic and therapeutic vaccine against HIV.
Patent CZ-300365-B6 (CZ)
Title: Inhibitors of VIIa factor, process of their preparation and use
Inventor: KLINGLER OTMAR
IPC: C07K5/065
Filed: 2000-05-27
Abstract: In the present invention, there are described compounds of the general formula I, in which e1, Re2, Re91, Re92, Re93, Re94, Re95, Re96, Re97, r, s and are as specified in the Claims. The compounds of the general formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore describes processes for the preparation of compounds of the general formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
Patent CZ-293751-B6 (CZ)
Title: Imidazole derivatives as phosphodiesterase VII inhibitors intended for use in the preparation of pharmaceutical compositions
Inventor: EGGENWEILER MICHAEL
IPC: C07D495/04
Filed: 2000-10-10
Abstract: The present invention relates to the use of imidazole derivatives of the general formula I, in which Re1 represents a hydrogen atom, the A group, benzyl, indan-5-yl, 1,2,3,4-tetrahydronaphthalen-5-yl, dibenzothiophen-2-yl, or phenyl, being optionally substituted with mono-, di- or trisubstituted with the group Hal, A, A-CO-NH, benzyloxy, alkoxy containing 1 to 4 carbon atoms, COOH or COOA, Re2 represents a hydrogen atom or the group A, X denotes an oxygen or sulfur  atom, Hal denotes a fluorine, chlorine, bromine or iodine atom, A represents alkyl having 1 to 6 carbon atoms or cycloalkyl with 3 to 6 carbon atoms, and their physiologically acceptable salts and/or solvates as phosphodiesterase VII inhibitors in the preparation of pharmaceutical compositions intended for treating allergic diseases, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, autoimmune diseases, such as rheumatoid arthritis, disseminated sclerosis, CrohnÆs disease, diabetes mellitus or ulcerous colitis, further for treating osteoporosis, transplant rejection,, cachexia, tumor growth or tumor metastases, sepsis, memory disorders, aterosclerosis and AIDS.
Patent CZ-296851-B6 (CZ)
Title: Process for producing paper or paper board
Inventor: CHEN GORDON CHENG I
IPC: D21H17/43
Filed: 2000-11-02
Abstract: In the present invention, there is disclosed a process for producing paper or paper board, said process comprising forming a cellulosic suspension, flocculating the suspension, draining the suspension on a screen to form a sheet and then drying the sheet, wherein the cellulosic suspension is flocculated by addition of a water soluble cationic synthetic polymer having intrinsic viscosity of at least 4 dl/g. The flocculated suspension is the subjected to mechanical shearing and then it is re-flocculated by a subsequent addition of a re-flocculating system, wherein the re-flocculating system comprises i) a siliceous material and ii) a water soluble anionic polymer having intrinsic viscosity of at least 4 dl/g, whereby the invented preparation process is characterized in that either, the siliceous material and water soluble anionic polymer are added to the suspension simultaneously or the siliceous material is added before or after the addition of the water soluble anionic polymer. The siliceous material (i) and water soluble anionic polymer (ii) are added to the cellulosic suspension downstream a centrifugal screen and the cationic polymer is added to a thin cellulosic suspension.
Patent SK-287800-B6 (SK)
Title: A bacterium Escherichia which has a potentiated activity in aspartate-semialdehyde dehydrogenase or phosphoenolpyruvate carboxylase and process for producing L-lysine
Inventor: NAKANISHI KAZUO
IPC: C12N15/52
Filed: 2000-01-21
Abstract: A method for producing L-lysine, which comprises culturing Escherichia coli in a suitable medium to produce and accumulate L-lysine in culture and collecting the L-lysine from the culture.
Patent SK-285209-B6 (SK)
Title: Matrix tablet for the prolonged release of gliclazide after oral administration and method for the preparation thereof
Inventor: HUET DE BAROCHEZ BRUNO
IPC: A61K9/22
Filed: 1999-10-15
Abstract: Matrix tablet for the prolonged release of gliclazide allowing continuous and regular release of active ingredient after oral administration, whereby the release is independent of the pH change of the dissolution medium.
Patent CU-23781-B7 (CU)
Inventor: HAAS JULIA
IPC: A61K31/08
Filed: 2008-04-07
Abstract: Macrocyclic compounds having the structures described herein are useful for inhibiting replication of the hepatitis C virus (HCV). In preferred embodiments, the compounds are active against both the NS3 protease and the NS3 helicase of HCV.
Patent BR-PI0314038-B8 (BR)
Title: anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
Inventor: ALISON WITTE
IPC: C07K16/28
Filed: 2003-09-05
Abstract: anticorpo humano isolado, método de tratar uma doença mediada com il-1 em um paciente, composição farmacêutica, cadeias pesada e leve, e, método de mapeamento de epitopo de um antígeno selecionado. descreve-se anticorpos que interagem com receptor de tipo 1 de interleucina-1 (il-1r1). descreve-se métodos de tratar doenças mediadas com il-1 mediante administração de uma quantidade farmaceuticamente eficaz de anticorpos para il-1r1. métodos de detectar a quantidade de il-1r1 em uma amostra utilizando-se anticorpos para il-1r1.
Patent GB-2434419-B8 (GB)
Title: Braking device for child seat
Inventor: CHEN SHUN-MIN
IPC: B62B9/08
Filed: 2006-08-11
Granted: 2008-01-30
Abstract: A braking device for a child seat is provided. The braking device comprises a first and second braking rods (20a, 20b), first and second braking pins (30a, 30b) and a braking pedal mechanism (40), the braking device being provided in a connecting tube (11) between two rear wheels (10a, 10b). When the brake pedal mechanism (40) rotates with respect to the connecting tube (11) in a direction, the braking rods (20a, 20b) move outward such that the outer ends (22a, 22b) of the braking rods (20a, 20b) are engaged with the rear wheels (10a, 10b) respectively, thereby completing the locking of the rear wheels (10a, 10b), and when the brake pedal mechanism (40) rotates with respect to the connecting tube (11) in another direction, the braking rods (20a, 20b) move inward such that the outer ends (22a, 22b) of the braking rods (20a, 20b) are disengaged from the rear wheels (10a, 10b) respectively, thereby completing the releasing of the rear wheels (10a, 10b).
Patent CH-713844-B8 (CH)
Title: Dispositif Micro-optique à Effet Optique Double Face.
Inventor: KARLO IVAN JOLIC
IPC: G02B30/30
Filed: 2017-04-13
Abstract: L'invention concerne un dispositif micro-optique, comportant un substrat transparent ; des premiers éléments de lentille sur un premier côté du substrat qui révèlent des premiers éléments d'image sur un deuxième côté du substrat ; et des deuxièmes éléments de lentille sur le deuxième côté du substrat qui révèlent des deuxièmes éléments d'image sur le premier côté du substrat L'invention concerne aussi un dispositif de sécurité (270) comportant ledit dispositif micro-optique.
Patent EP-1103492-B8 (EP)
Inventor: ADELMANN DIETER
IPC: F16J13/18
Filed: 2000-11-23
Granted: 2005-04-06
Abstract: Device for closing an opening (1) arranged in the base of a container comprises a lid (2) on a tilting shaft (4) over a supporting arm (3). The lid is connected to the arm and can move opposite the arm about a tilting axis (6). An apparatus is provided for regulating and/or controlling the position of the lid in relation to the opening so that the lid can be lifted when it enters the opening in a translatory fashion and parallel to the central axis (8) of the lid. An Independent claim is also included for a process for operating the closing device.
Patent EP-1358562-B8 (EP)
Title: Procede et appareil permettant de commander les flux de donnees entre des systemes informatiques via une memoire
Inventor: BIRAN GIORA
IPC: G06F13/40
Filed: 2001-01-31
Granted: 2012-03-28
Abstract: La présente invention concerne un appareil qui permet de commander les flux de données entre un premier et un second système informatique via une mémoire.  L'appareil de l'invention comprend une logique de description qui permet de créer une pluralité de descripteurs comprenant un descripteur de trame qui définit un paquet de données à communiquer entre un emplacement en mémoire et le second système informatique, et un descripteur pointeur qui identifie l'emplacement en mémoire.  L'appareil précité comprend également une table de description destinée à stocker les descripteurs créés par la logique de description afin que le premier et le second système informatique puissent y avoir accès.
Patent EP-1249193-B8 (EP)
Inventor: WEIDENBACH DIETER
IPC: A47F3/04
Filed: 2002-04-05
Granted: 2007-02-14
Abstract: The chill cabinet has an air inlet (9) at the front, near the base. Air is sucked through this, over an evaporator (7), and is then circulated over the shelves (5). It is then recirculated through an aperture (10) above the evaporator.
Patent EP-1426976-B8 (EP)
Inventor: KIRKINSKII VITALII ALEKSEEVITCH
IPC: G21B1/11
Filed: 2002-07-17
Granted: 2010-07-07
Abstract: The invention relates to the power production using deuterium nuclear interaction in the crystalline structures of deuterides of palladium and other metals activated during phase transitions. The inventive device comprises a reactor containing a working substance, a system for measuring and controlling a gas pressure, a system for heating and temperature control, a system for transferring and using the released heat. The reactor (1) containing the working substance (13) and capable to undergo isostructural phase transformations accompanied by the modification of the deuterium content is embodied in the form of coaxially disposed pipes (2 and 3) provided with valves (4 and 5) which seal the volume therebetween. Heaters (14 and 15) are arranged at the end of said pipes in such a way that it is possible to produce a directionally variable temperature gradient along the longitudinal axis of the reactor. The heat exchanger of a primary circuit (22) is embodied in the form of coaxial pipes (23 and 24) between which a heat carrier (29) passes, and butted against the reactor on the side radially opposite to the position of the heaters. Various modifications of the inventive device enabling to carry out the simultaneous desorption and sorption of deuterium in the working substance on the opposite sides of the reactor, efficiently transfer and use the released excess heat, increase the reliability of the operation and to provide the conditions for the automation thereof are also disclosed.
Patent EP-1119773-B8 (EP)
Inventor: PRUSINER STANLEY B
IPC: C07K14/47
Filed: 1999-10-05
Granted: 2006-06-21
Abstract: An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrP<SUP>Sc</SUP>) present in a sample also containing the non-disease related conformation of the protein (e.g., PrP<SUP>C</SUP>). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a labeled antibody which binds PrP<SUP>Sc</SUP>) and the occurrence of binding provides and indication that PrP<SUP>Sc </SUP>is present. Alternatively the PrP<SUP>Sc </SUP>of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrP<SUP>Sc </SUP>is contacted with a binding partner and the occurrence of binding indicates the presence of PrP<SUP>Sc </SUP>in the sample. In another embodiment, PrP<SUP>Sc </SUP>and PrP<SUP>C </SUP>are reacted with a labeled antibody that binds both conformations and a conformation that binds only the disease related conformation, and the presence of the disease related conformation is determined by comparing the two.
Patent BR-PI0113757-B8 (BR)
Title: derivados de quinolinona como inibidores de tirosina quinase
Inventor: BILL MCCREA
IPC: A61K31/4709
Filed: 2001-09-11
Abstract: "derivados de quinolinona como inibidores de tirosina quinase". são fornecidos compostos orgânicos tendo as fórmulas i e ii onde as variáveis têm os valores descritos nessa. formulações farmacêuticas incluem os compostos orgânicos ou sais farmaceuticamente aceitáveis desses e um transportador farmaceuticamente aceitável e podem ser preparadas por mistura dos compostos orgânicos ou sais farmaceuticamente aceitáveis dos compostos orgânicos com um transportador e água. um método de tratamento de um paciente inclui a administração de uma formulação farmacêutica de acordo com a invenção a um paciente em necessidade dela.
Patent BR-PI0415562-B8 (BR)
Title: método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio
Inventor: SHIGEHIKO MIZUTANI
IPC: G01N33/574
Filed: 2004-09-15
Abstract: reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma. a presente invenção proporciona um reagente para avaliação prognóstica de pacientes com carcinoma, compreendendo um anticorpo anti-p-lap como um ingrediente ativo. também, a presente invenção proporciona um método para a determinação de p-lap que é um fator prognóstico em pacientes com carcinoma compreendendo (a) uma etapa de contatar tecidos de carcinoma obtidos de pacientes com carcinoma por operação cirúrgica com um anticorpo anti-p-lap e (b) uma etapa de medir a intensidade da reação específica de antígeno-anticorpo entre p-lap presente nos tecidos de carcinoma e o anticorpo anti-p-lap.
Patent BR-PI0519285-B8 (BR)
Title: método para produzir um biomaterial implantável resistente a calcificação, biomaterial implantável resistente a calcificação, dispositivo biológico implantável, implante biocompatível, kit para reparar uma lesão de tecido, curativo de ferimentos
Inventor: ANDREW JULIAN HODGE
IPC: A61F2/24
Filed: 2005-12-20
Abstract: biomaterial implantável e método de produzir o mesmo. a presente invenção se refere a um biomaterial implantável e métodos para produzi-lo. em particular, a invenção se refere a um método para produzir um biomaterial implantavel compreendendo (a) expor um biomaterial implantavel a uma solução contendo álcool por pelo menos 24 horas.
Patent BR-PI0712098-B8 (BR)
Title: composição farmacêutica oralmente administrável para liberação intestinal específica local de adsorventes e uso da mesma
Inventor: ANTOINE ANDREMONT
IPC: A61K33/44
Filed: 2007-05-18
Abstract: distribuição intestinal específica local de adsorventes, sozinhos ou em combinação com moléculas de degradação. composições que distribuem adsorventes, sozinhos ou em combinação com "moléculas de degradação" de fármaco ativa em uma maneira específica local ao intestino, e que eliminam ou pelo menos diminuem a concentração de material indesejado residual dentro do intestino, são reveladas. métodos de tratamento usando as composições são também revelados. o material a ser eliminado pode incluir antibióticos ativos residuais, metabólitos, toxinas bacteriais ou outras, e fármacos que causam efeitos colaterais no trato gastrointestinal. os adsorventes podem ser formulados em cápsulas, comprimidos ou qualquer composição farmacêutica aceitável, e são idealmente designados para liberar especificamente os adsorventes em uma maneira programada em um local específico do trato intestinal. a distribuição programada impede os adsorventes de interferir com o processo de absorção normal de uma dada molécula após absorção oral, até que ele alcança a parte inferior do intestino delgado. as composições podem ser usadas para adsorver, e, portanto, remover qualquer fármaco residual, metabólito desta, ou toxina bacterial após administração oral ou parenteral que, de outro modo, causaria efeitos adversos no intestino inferior e/ou cólon.
Patent BR-PI0808311-B8 (BR)
Title: dispositivo de irrigação nasal
Inventor: MARTIN R HOKE
IPC: A61N1/30
Filed: 2008-03-06
Abstract: dispositivo de irrigação nasal e método para irrigação de uma cavidade nasal trata-se de sistemas e métodos para irrigação nasal em que um dispositivo de irrigação nasal inclui uma fonte de solução salina, um receptáculo de efluente, uma interface nasal, uma fonte de vácuo, uma passagem de fluido para comunicar a fonte de solução salina com o receptáculo de efluente através da interface nasal e da cavidade nasal do usuário, e um conjunto de interruptor e válvula que controlam seletivamente a fonte de vácuo e o fluxo de solução salina através da passagem de fluido. o frasco de fonte de solução salina é disposto em relação ao dispositivo para fornecer a indução gravitacional da solução salina para a interface nasal ao acoplar as narinas do usuário ao dispositivo. uma combinação de indução gravitacional e vácuo relativo de um receptáculo de efluente gera um fluxo fluido para irrigação, limpeza e massagem da cavidade nasal e do óstio de um usuário.
Patent AU-2005330574-B8 (AU)
Title: Active foam
Inventor: YAMAMOTO TOMIZO
IPC: A61N1/00
Filed: 2005-05-16
Granted: 2012-01-19
Abstract: An active foam, which is made of natural rubber, a synthetic rubber or a synthetic resin containing a zirconium compound and/or a germanium compound, characterized in that it has a closed-cell structure and is used by directly or indirectly bringing it into contact with the human body upon drug administration is provided. By directly or indirectly bringing the active foam into contact with the human body, blood circulation can be promoted, the physical condition can be improved, or cure of a disease can be accelerated. Further, there is no side effect.
Patent AU-2006215370-B8 (AU)
Title: Optimized multicast distribution within a hybrid PPPoE/IPoE broadband access network
Inventor: ANDERSEN OLE HELLEBERG
IPC: H04L69/168
Filed: 2006-02-14
Granted: 2010-07-08
Abstract: An access node (e.g., DSLAM) and method for optimizing the distribution of a multicast stream within a hybrid PPPoE/IPoE broadband access network are described herein. In the preferred embodiment, the DSLAM snoops upstream IGMP messages encapsulated within PPPoE frames, and forwards them transparently towards a BRAS (located in an Ethernet aggregation network). In addition, the DSLAM duplicates the IGMP message and sends the duplicated IGMP message encapsulated within IPoE frames towards the standard Ethernet switches (located in the Ethernet aggregation network). The IPoE encapsulated IGMP message can be snooped by the standard Ethernet switches. This functionality of the DSLAM ensures the optimal multicast distribution by the Ethernet aggregation network.